Approval of revisions to key EU clinical investigation guidelines just out of reach
This article was originally published in Clinica
The proposed revisions to two key EU guidelines on medical device clinical investigations have faced a slight delay to their final approval. One guideline, Meddev 2.7/ 2, is on competent authority assessment of a clinical investigation and the other, Meddev 2.7/3, is related to the reporting of serious adverse events (SAEs) during an investigation.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% in costs for some equipment during COVID-19 emergency measures as the UK tries to increase supplies